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Abstract 
Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown 
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based 
therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US 
FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic 
leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. Despite the 
progresses made in treating hematological malignancies, challenges still remain for use of CAR-T cell 
therapy to treat solid tumors. In this landscape, most studies have primarily focused on improving 
CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. 
To further understand the current status and trend for developing CAR-T cell based therapies for 
various solid tumors, this review emphasizes on CAR-T techniques, current obstacles, and 
strategies for application, as well as necessary companion diagnostics for treatment of solid tumors 
with CAR-T cells. 
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Introduction 
Immunotherapy with CAR-T cells has achieved 
tremendous successes in treatment of hematological 
malignancies. Two CD19-targeting CAR-T cell 
products, Kymriah from the Novartis (East Hanover, 
NJ USA) and Yescarta from the Kite Pharma (Santa 
Monica, CA USA), have been approved by the US 
FDA for treating B cell acute lymphoblastic leukemia 
(B-ALL) and diffuse large B-cell lymphoma (DLBCL), 
respectively [1]. However, due to intricacies of solid 
tumors and their locations in the human body, 
treatment of solid tumors with CAR-T cells is facing 
multiple obstacles, such as the hostile tumor 
microenvironment, on-tumor/off-tumor toxicities, 
and undesired antigen specificity [2]. Many strategies 
and approaches have been tried to overcome these 
obstacles, including arming CAR-T cells with 
knock-out of PD-1 expression or secretion of 
cytokines/chemokines and using CAR-T cells in 
combination with other treatments [3-5]. Despite these 
efforts, there are still no CAR-T cells clinically 
approved for solid tumor treatment so far. 
Encouragingly and optimistically, in this landscape, 
more than forty clinical trials in treatment of solid 
tumors by CAR-T cells have been registered in China 
alone (Table 1) [6]. 
Beside the focuses on the aspects of treatment, 
companion diagnostics are increasingly recognized as 
playing important roles in patient screening, 
treatment regimen, efficacy evaluation, and real-time 









review, we focus on current CAR-T techniques, 
obstacles, strategies for overcoming these obstacles, as 
well as necessary companion diagnostics in treatment 
of solid tumors with CAR-T cells.  
 
Table 1. Clinical trials in treatment of solid tumors in China by CAR-T cells 
Antigen Tumor target Sponsor Phase NCT number Study start 
CD133 Liver cancer; pancreatic cancer; brain tumor; breast 
cancer; ovarian tumor; colorectal cancer, acute myeloid 
lymphoid leukemias 
Chinese PLA General Hospital Phase 1 NCT02541370 2015 
CD138 Multiple myeloma Chinese PLA General Hospital Phase 1/Phase 2 NCT01886976 2013 
CD19 Recurrent or refractory B-cell tumor Second Military Medical University Phase 1/Phase 2 NCT02644655 2015 
CEA Lung cancer; colorectal cancer; gastric 
cancer; breast cancer; pancreatic cancer 
Southwest Hospital Phase 1 NCT02349724 2014 
Claudin 18.2 Advanced gastric adenocarcinoma, pancreatic 
adenocarcinoma 
Changhai Hospital NA NCT03159819 2017 
EGFR Advanced EGFR-positive solid tumors Chinese PLA General Hospital Phase 1/Phase 2 NCT01869166 2013 
EGFR Advanced glioma RenJi Hospital Phase 1 NCT02331693 2014 
EGFR Advanced solid tumor Shanghai Cell Therapy Research Institute Phase 1/Phase 2 NCT03182816 2017 
EGFR EGFR-positive colorectal cancer Shenzheng Second People’s Hospital Phase 1/Phase 2 NCT03152435 2017 
EGFRvIII Recurrent glioblastoma multiforme Beijing Sanbo Brain Hospital Phase 1 NCT02844062 2016 
EGFRvIII Glioblastoma multiforme Shenzhen Geno-Immune Medical Institute Phase 1/Phase 2 NCT03170141 2017 
EphA2 EphA2-positive malignant glioma Fuda Cancer Hospital Phase 1/Phase 2 NCT02575261 2015 
EpCAM Liver neoplasms Sinobioway Cell Therapy Co., Ltd. NA NCT02729493 2015 
EpCAM Stomach neoplasms Sinobioway Cell Therapy Co., Ltd. NA NCT02725125 2015 
EpCAM Malignant neoplasms of the nasopharynx, TNM staging, 
distant metastasis and breast cancer recurrence 
Sichuan University Phase 1 NCT02915445 2016 
EpCAM Colon cancer, esophageal carcinoma, pancreatic cancer, 
prostate cancer, gastric cancer, hepatic carcinoma 
First Affiliated Hospital of Chengdu 
Medical College 
Phase 1/Phase 2 NCT03013712 2017 
GD2 Neuroblastoma Zhujiang Hospital Phase 2 NCT02765243 2016 
GD2 Relapsed or refractory neuroblastoma Sinobioway Cell Therapy Co., Ltd. NA NCT02919046 2016 
GD2 Solid tumor Shenzhen Geno-Immune Medical Institute Phase 1/Phase 2 NCT02992210 2016 
GPC3 Hepatocellular carcinoma RenJi Hospital Phase 1 NCT02395250 2015 
GPC3 Hepatocellular carcinoma and liver metastases Shanghai GeneChem Co., Ltd. Phase 1/Phase 2 NCT02715362 2016 
GPC3 GPC3-positive hepatocellular carcinoma Funda Cancer Hospital, Guangzhou Phase 1/Phase 2 NCT02723942 2015 
GPC3 Lung squamous cell carcinoma Carsgen Therapeutics, Ltd. Phase 1 NCT02876978 2016 
GPC3 Hepatocellular carcinoma Shanghai GeneChem Co., Ltd. Phase 1/Phase 2 NCT03130712 2017 
GPC3 Advanced hepatocellular carcinoma Xinqiao Hospital of Chongqing Phase 1/Phase 2 NCT03084380 2017 
GPC3 Hepatocellular carcinoma, squamous cell lung cancer Second Affiliated Hospital of Chengdu 
Medical University 
Phase 1 NCT03198546 2017 
GPC3 Hepatocellular carcinoma RenJi Hospital - NCT03146234 2017 
GPC3/MSLN/ 
CEA 
Hepatocellular, pancreatic cancer, colorectal cancer Shanghai GeneChem Co., Ltd. Phase 1/Phase 2 NCT02959151 2016 
HER2 Tumors refractory to chemotherapy and/or HER2 
antibody therapy, advanced HER2-positive solid tumors 
Chinese PLA General Hospital Phase 1/Phase 2 NCT01935843 2013 
HER2 Breast cancer, ovarian cancer, lung cancer, gastric cancer, 
colorectal cancer, glioma, pancreatic caner 
Southwest Hospital Phase 1/Phase 2 NCT02713984 2016 
HER2 Breast cancer Fudan Cancer Hospital Phase 1/Phase 2 NCT02547961 2015 
HerinCAR-PD1 Advanced malignancies Ningbo Cancer Hospital Phase 1/Phase 2 NCT02873390 2016 
HerinCAR-PD1 Advanced solid tumors (lung, liver, and stomach) Shanghai International Medical Center Phase 1/Phase 2 NCT02862028 2016 
MSLN Malignant mesothelioma, pancreatic cancer; ovarian 
tumor; triple negative breast cancer; endometrial cancer; 
other mesothelin-positive tumors 
Chinese PLA General Hospital Phase 1 NCT02580747 2015 
MSLN Pancreatic cancer Shanghai GeneChem Co., Ltd. Phase 1 NCT02706782 2016 
MSLN Mesothelin-positive tumors China Meitan General Hospital Phase 1 NCT02930993 2016 
MSLN Solid tumors, adult advanced cancer Ningbo Cancer Hospital Phase 1/Phase 2 NCT03030001 2017 
MSLN Advanced solid tumors Shanghai Cell Therapy Research Institute Phase 1/Phase 2 NCT03182803 2017 
MG7 Liver metastases Xijing Hospital Phase 1/Phase 2 NCT02862704 2016 
MUC1 Malignant glioma of the brain; colorectal carcinoma; 
gastric carcinoma 
PersonGen Biomedicine (Suzhou) Co., Ltd. Phase 1/Phase 2 NCT02617134 2015 
MUC1 Advanced refractory solid tumors (hepatocellular 
carcinoma, NSCLC, pancreatic carcinoma, triple-negative 
invasive breast carcinoma) 
PersonGen Biomedicine (Suzhou) Co., Ltd. Phase 1/Phase 2 NCT02587689 2015 
MUC1 Advanced solid tumors Shanghai Cell Therapy Research Institute Phase 1/Phase 2 NCT03179007 2017 
NY-ESO-1 Advanced NSCLC Guangzhou Institute of Respiratory 
Disease 
Phase 1 NCT03029273 2017 
LMP1 Nasopharyngeal neoplasms The Second Hospital of Nanjing Medical 
University 
Phase 1/Phase 2 NCT02980315 2016 




Advanced lung or other cancers Second Affiliated Hospital of Guangzhou 
Medical University 
Phase 1 NCT03198052 2017 
PSMA/FRα Bladder cancer, urothelial carcinoma bladder Shenzhen Geno-Immune Medical Institute Phase 1/Phase 2 NCT03185468 2017 
Zeushield NSCLC Second Xiangya Hospital of Central South 
University 
Phase 1 NCT03060343 2016 
*The clinical trials are collected from clinicaltrials.gov 





Overview of CAR-T techniques 
Chimeric antigen receptor (CAR) is the core 
component of CAR-T, which endows T cells with the 
ability to recognize tumor antigens in a 
HLA-independent manner and enables them to 
recognize more extensive target antigens than natural 
T cell surface receptor (TCR) [7]. A basic CAR 
includes a tumor-associated antigen (TAA) binding 
domain (usually from the scFv fragment of 
antigen-binding region of the monoclonal antibody), 
an extracellular hinge domain, a transmembrane 
domain and an intracellular signal domain [7, 8]. 
The activation of T cells mediated by the first 
generation of CAR is accomplished by the tyrosine 
activation motif on CD3ζ chain or FcεRIγ [9]. CD3ζ 
chain can provide “signal I” for T cell activation, 
cytolysis, regulation of IL-2 secretion and anti-tumor 
activity in vivo [10, 11]. However, the anti-tumor 
activity of the first generation of CAR modified T cells 
is limited in vivo, and the decreased proliferation of T 
cells ultimately leads to apoptosis [12, 13]. The second 
generation of CAR adds a new costimulatory signal in 
the intracellular region, which enlarges the original 
“signal I” derived from TCR/CD3 complex [14, 15]. 
Many studies have shown that compared with the 
first generation of CAR, the second generation of CAR 
carrying “signal II” has the same antigen specificity, 
increased T cell proliferation and cytokine secretion, 
enhanced secretion of anti-apoptotic proteins, and 
delayed cell death. The ubiquitously used 
costimulatory molecule is CD28 [16, 17], which have 
been gradually been replaced with CD137 (4-1BB) 
[18]. In addition, an idea of using NK cell receptor 
CD244 has also been proposed to promote sustained 
activation and proliferation of CAR-T cells [19]. 
In order to further improve the design of CAR, 
many studies began to focus on the development of 
the third generation of CAR, including not only 
“signal I”, “signal II”, but also additional 
costimulatory signals. Studies using different targets 
and costimulatory signals were conducted to compare 
the results of the second and third generation of CARs 
and obtained quite encouraging experimental results 
[20, 21]. Zhong et al. combined CD28 and 4-1BB 
costimulatory signaling domains to construct a CAR 
specific for prostate-specific membrane antigen 
(PSMA). This group demonstrated that the CAR they 
constructed was able to induce strongest PI3K/Akt 
activation and Bcl-XL expression in vitro, and the least 
apoptosis in transduced peripheral blood CD8+ T cells 
[20]. Targeting a different tumor marker, MUC1, 
Wilkie et al. designed a CAR containing a fused 
CD28/OX40/CD3ζ endodomain. Using the 
engineered CAT-T cells and upon MUC1 stimulation, 
they showed that these CAR-T cells were able to 
secrete proinflammatory cytokines indicative of both 
type-1 (IFN-γ) and Th17 (IL-17) differentiation in 
vitro. It was noteworthy that IL-17 has been known as 
tissue destructive cytokine in autoimmune disease 
animal models, although its anti-tumor effect is still to 
be elucidated [20, 21].  
Up to date, it is still uncertain which design is 
better between the second generation and the third 
generation of CAR. Additionally, the second and third 
generations of CARs have their own on-going clinical 
trials in the US, China and Europe, and the 
development and outcome of these clinical trials are 
being closely watched.  
Obstacles in treating solid tumors with 
CAR-T cells 
1. CAR-T cells traffick to the tumor sites 
To bind to their target proteins on the surface of 
tumors, CAR-T cells first need to traffick to tumor 
sites. This is the fundamental prerequisite for T cell 
immunotherapy to work properly. Unlike the 
hematological malignancies, in the case of solid 
tumors, T cells trafficking to and infiltrating into 
tumor sites are oftentimes greatly limited by the 
immunosuppresive microenvironment [22]. Also 
unlike hematological malignancies that are easy to be 
targeted and reached by CAR-T cells, some of 
chemokines such as CXCL1 [23], CXCL12, and CXCL5 
[24, 25] secreted by solid tumors prevent T cells from 
trafficking toward and infiltrating into the tumor 
lesions. Due to lack of corresponding chemokine 
receptors expressed on T cells, it is difficult for them 
to traffic and infiltrate into tumor sites, drastically 
impeding the ability of CAR-T cells for their designed 
immuno-cytotoxicity for killing tumor cells. 
Therefore, in order to overcome this obstacle, T cell 
will need to be modified to express chemokine 
receptor that matches the corresponding 
tumor-derived chemokine. An early study conducted 
by Kershaw et al. demonstrated that chemokine 
receptor (CXCL1 receptor)-engineered T cells can 
greatly drive themselves to migrate toward 
melanoma cells [23]. This study demonstrated the 
feasibility that T cell traffic can be re-directed to tumor 
sites by chemokines secreted by tumor cells. 
2. CAR-T cells infiltrate into tumors 
Once CAR-T cells successfully traffic to tumor 
sites, infiltrating into tumor microenvironment is a 
required critical step to exert anti-tumor effects. This 
is a very highly dynamic and regulated complex step: 
it involves rolling, adhesion, extravasation and 
chemotaxis [26]. Solid tumors have unique 
histopathological features, such as concentrated blood 
vessels [27], as well as tumor-associated fibroblasts 





and myeloid cells forming extracellular matrix (ECM). 
While these features favor the growth of solid tumors, 
they impose the difficulty for T cell infiltration in 
tumor sites [27], thus preventing the continuous 
contact between T cells and tumor cells that is neces-
sary for T cells to exert cytotoxic antitumor effects.  
3. The immunosuppressive state of 
microenvironment in solid tumors  
The immunosuppressive microenvironment 
within solid tumor has special histopathological 
features as manifested by high density blood vessels, 
extensive vascular leakage, poor integrity of tissue 
structure, and others [2]. These changes result in 
hypoxia, low pH, immune suppressor cells, augment 
of inhibitory checkpoint, and more tumor-derived 
cytokines [28-30]. Following are three major factors 
that affect the antitumor effects of T cells: 
3.1 Immune suppressor cells 
Solid tumors generally consist of a large number 
of immune suppressor cells, such as regulatory T cells 
(Tregs), myeloid-derived suppressor cells (MDSCs), 
and tumor-associated macrophages. These cells all 
play roles to protect solid tumor cells from being 
killed by the host’s immune system. Theoretically, 
costimulatory molecules, such as CD28 and CD137, 
may benefit CAR-T cell activation and survival in 
tumor sites [31, 32]. In addition, blocking 
granulocyte-macrophage colony stimulating factor 
(GM-CSF) dependent MDSC expansion and PD-L1 
expression on MDSC may be a potential approach to 
enhance the antitumor effects of CAR-T cells [33].  
3.2 Tumor-derived cytokines 
Tumor-derived cytokines are soluble factors that 
deter the efficacy of cancer immunotherapy for solid 
tumors. Transforming growth factor-β (TGF-β) is an 
inhibitory tumor cytokine that plays a major role in 
alleviating the antitumor response. TGF-β 
downregulates CD8+ effector T cell function and 
upregulates Treg maturation [27]. In contrast, 
neutralizing TGF-β by antibody or small molecular 
drugs improves CD8+ T cell functions and enhances 
the antitumor response by increasing the number, 
infiltration and persistence of adoptively transferred T 
cells. Moreover, the activation of cytokines, such as 
interleukin (IL)-2 and IL-15, improves the antitumor 
effects of CAR-T cells [34]. IL-12, in particular, alters 
the tumor microenvironment [35], eliminates 
antigen-negative tumor cells [36], and prolongs the 
survival of T cells to increase efficacy of 
immunotherapy through recruiting and activating 
macrophages and other innate immune cells [27]. In 
addition, to alter the tumor microenvironment, 
armored CAR-T cells have been generated to secrete 
proinflammatory cytokines to improve CAR-T cell 
efficacy within the tumor microenvironment [37]. 
3.3 Checkpoint inhibitory ligands 
Inhibitory immune-checkpoint ligands induce 
the suppressive function of the immune response and 
are usually overexpressed in solid tumors. For 
example, PD-L1 is ligand for PD-1 receptor and 
inhibits CAR-T cell activation by binding to PD-1. 
PD-L1 has the two function motifs, immune-receptor 
tyrosine-based inhibitor motif (ITIM) and 
immune-receptor tyrosine-based switch motif (ITSM), 
which are involved in dephosphorylation of TCR- 
associated CD3 and zeta chain-associated protein 
kinase 70 (ZAP70) [27, 38]. Blocking PD-1 through 
specific antibody, shRNA, or dominant negative 
receptor restored the function of Mesothelin-targeting 
CD28 CAR T cells, and CAR-T cells with constitutive 
anti-PD-1 secretion were more functional, 
expandable, and efficient in tumor eradication than 
parental CAR-T cells in a human lung carcinoma 
xenograft mouse model [39, 40]. Checkpoint 
blockades are being applied to many clinical trials in 
combination treatment with CAR-T cells [41, 42]. 
4. The immune-related adverse events(irAEs)  
One of the major challenges in CAR-T cell 
therapy for solid tumors is the irAEs [43-46]. In 2010, 
death of a patient with colon cancer metastasis to the 
lung and liver following ERBB2-targeting CAR-T cell 
therapy was reported. The cause may be due to the 
recognition of CAR-T cells to low levels of ERBB2 on 
lung epithelial cells and resulted in triggering the 
release of remarkable amount of cytokines [43]. There 
are two major mechanisms leading to the increased 
toxicity observed with CAR-T cell therapy: 
4.1 On-target/on-tumor toxicity 
The most life-threatening toxicity following 
CAR-T cell immunotherapy is on-target/on-tumor 
toxicity, which relates to adverse effects, such as 
cytokine release syndrome (CRS). Upon binding to 
antigens on target tumor cells, infused CAR-T cells 
are extensively activated, leading to the release of a 
large number of inflammatory cytokines. The CRS 
symptoms include fever, fatigue, nausea, vomiting, 
diarrhea, rashes, delirium, hallucinations, 
hypotension, and even severe multiple organ failure 
[44, 47]. The CRS has been classified into five grades 
according to the Common Terminology Criteria for 
Adverse Events (CTCAE) ranging from a mild 
reaction/grade 1 to death/grade 5. The level of the 
CRS severity is believed to be strongly correlated with 
tumor burden. IL-6 appears to be a major mediator of 
the CRS [48], and thus the key strategy to ameliorate 
this side effect is to block IL-6 directly with the IL-6R 





inhibitor tocilizumab [49]. In addition to tocilizumab, 
new cytokine-directed approaches might be 
considered to overcome the CRS.  
4.2 On-target/off-tumor toxicity 
Another type of toxicity originates from binding 
of CAR-T cells to target antigen that is also expressed 
on normal cells. This toxicity may lead to destruction 
of healthy cells and organs [43]. In the treatment of 
neuroblastoma, the fatal neurotoxicity was observed 
in high-affinity GD2-specific CAR-T cell therapy, 
suggesting that GD2 may be an inappropriate 
targeting antigen for CAR-T cell therapy [50]. Most of 
the CAR-T cell target antigens seem not to be tumor 
specific and shared by normal cells. Therefore, 
antigen specificity becomes a crucial factor for CAR-T 
therapy. To reduce the risk of this toxicity, selectivity 
of a safer antigen for CAR-T cells is critical and may 
be improved by utilizing dual CAR targeting, and 
modulating the sensitivity of single-chain variable 
fragment (scFv) [51]. Toxicity can also be minimized 
by controlling CAR-T cell activity through 
manipulating CAR expression and introducing a 
switch that can be triggered in the severe condition of 
the irAE [52, 53].  
5. Antigen specificity 
Tumor cells exhibit different morphologic and 
phenotypic profiles. One of the predominant 
biological characteristics of solid tumors is their 
heterogeneity. Tumor heterogeneity significantly 
affects immunotherapy efficacy due to the immune 
target may limit to a certain population of solid tumor 
cells. Therefore, to improve target specificity and 
eliminate toxicity are necessary in CAR-T cell therapy. 
EGFR variant III (EGFRvIII) is believed to be the only 
tumor-specific antigen (TSA) for CAR-T cells. It is 
found to be exclusively expressed on human cancer 
cells rather than normal healthy cells [54-56], 
EGFRvIII-targeting CAR-T cells precisely target 
tumor cells and are helpful to increase efficacy and 
reduce toxicity.  
The shortage of TSAs severely limits the use of 
CAR-T therapy. Therefore, targeting tumor-associated 
antigens (TAAs) is an alternative method to overcome 
the shortage of TSAs. Most of ongoing clinical trials of 
CAR-T cell therapies for solid tumors are using these 
TAAs [57]. Attention should be paid to use of this 
CAR-T strategy because it may cause damage of 
normal tissues as TAAs are not only overexpressed on 
tumor cells but also on some normal cells.  
6. Strategies to refine CAR-T cells for 
treatment of solid tumors 
To overcome the obstacles mentioned above, we 
need to improve T cell efficacy and adopt new 
strategies that are discussed as below:  
6.1 Improving CAR-T cell trafficking and infiltration 
As mentioned earlier, CAR-T cell trafficking 
requires the establishment of chemotaxis migration 
between chemokines secreted by tumor cells and 
chemokine receptors on effector T cells. Different 
tumor types produce various chemokines so that a 
corresponding chemokine with its appropriate 
chemokine receptor is a critical factor for successful 
trafficking of T cells to tumor sites [22]. T cells 
engineered with the chemokine receptor CXCR2, 
which binding to the ligand CXCL1 on tumor cells, 
have been demonstrated to effectively traffick toward 
melanoma (Figure 1A) [23]. Di Stasi et al. 
demonstrated that the anti-lymphoma effects of T 
cells were improved by co-expression of CCR4. CCR4 
can enhance the homing of CAR-CD30-modified T 
cells to CD30+ Hodgkin lymphoma cells by its 
secreted CCL17 (ligand for CCR4) [58]. Similarly, the 
antitumor effects towards malignant pleural 
mesothelioma and neuroblastoma were improved by 
CCR2b expression of mesothelin- and GD2-targeting 
CAR-T cells, respectively [59]. The local delivery of 
IL-7 and CCL19 by CAR-T cells improved immune 
cell infiltration and CAR-T cell survival in the tumor 
[60]. Conversely, tumor cells mediate the secretion of 
chemokines from suppressive immune cells, such as 
CXCL5, and the lack of suitable chemokine receptors 
on T cells, decrease migration of CAR-T cells into 
tumors (Figure 1A) [24, 25]. 
Regional delivery of T cell through 
intraperitoneal and intra-tumoral injection is also a 
direct way to deliver CAR-T cells. In a Phase I clinical 
trial study, ErbB-targeting CAR-T cells were delivered 
via intra-tumoral injection to patients with head and 
neck squamous cell carcinoma [61]. Local delivery is 
also suitable for other cancers, such as ovarian cancer 
and malignant pleural mesothelioma via the 
peritoneal and pleural cavities [22]. However, 
innovative deliveries are needed to be developed for 
those patients with tumors that are not easy to access 
by regional delivery. 
Stroma is mainly composed of ECM whose 
primary ECM component is heparan sulfate 
proteoglycan (HSPG) [22]. Degradation of HSPG is 
the first step for T cells to pass stroma-rich solid 
tumors. Heparanase (HPSE) is an enzyme that 
degrades HSPG. Reduction of HPSE mRNA 
expression has been found in in vitro-expanded 
CAR-T cells, thus restricting their anti-tumor function 
in solid tumors due to the abundance of stroma [62]. 
Caruanu, et al. had engineered CAR-T cells that 
express HPSE to promote T cell infiltration and 
antitumor activity. Their study showed improved 





capability of CAR-T cells to degrade the EMC [62]. 
Wang et al. demonstrated that fibroblast activation 
protein (FAP)-targeted CAR-T cells enhanced 
cytotoxic function by decreasing tumor fibroblasts in 
animal models [27]. VEGF receptor-2, highly 
expressed on tumor-associated endothelial cells, has 
been selected as another candidate for facilitating T 
cell infiltration [26]. CAR-T cells engineered with 
VEGF receptor-2 generated a durable and increased 
tumor infiltration and enhanced antitumor effect 
(Figure 1A) [63]. With anti-angiogenic pharmacologic 
intervention, tumor infiltration of CD8+ T cell is 
increased by blocking VEGF receptor-2 to achieve 
long-term therapeutic efficacy [64]. It is clear that the 
complexity of genetic modification and long-term 
period of in vitro culture may also limit the clinical 
application of CAR-T cell therapy. 
6.2 Reversal of the immunosuppressive 
microenvironment 
Preclinical data have shown that incorporation 
of costimulatory molecules into CARs helps CAR-T 
cells to reverse the immunosuppressive tumor 
microenvironment, for example, CD28 co-stimulation 
overcomes TGF-β-mediated repression of 
proliferation and enhances T-cell resistance to Treg 
cells [31, 32, 65]. Burga et al. showed that MDSCs are 
responsible for liver metastases and inhibition of 
CEA-targeted CAR-T cells. Following MDSC 
depletion in a mouse model, the antitumor activity of 
CAR-T cells was rescued [33]. During MDSC 
recruitment, tumor cells secrete high levels of 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF) in vivo. Thus, GM-CSF neutralization might 
be an alternative method to inhibit MDSC expansion 
(Figure 1) [66, 67]. 
Inhibition of immunosuppressive cytokines by 
introducing a dominant-negative TGF receptor on 
CAR-T cells also improves the efficacy of CAR-T cells 
[68]. In the tumor microenvironment, cytokine (e.g., 
IL-2, IL-12, and IL-15) activation could antagonize the 
effects of immunosuppressive factors and improve 
CAR-T cell efficacy. Studies have shown that the 
antitumor function is enhanced by CAR-T cells that 
 
 
Figure 1. A. Improving CAR-T cell trafficking and infiltration. 1) Targeting the tumor stroma or vasculature: tumor fibroblasts are depleted by FAP-targeting CAR-T 
cells to inhibit tumor growth. 2) ECM consumption by a secreted enzyme: the ECM (heparan sulfate proteoglycans) can be disintegrated by HPSE. 3) Homing to tumors 
expressing chemokine receptors (CCR4, CCR2b): genetically modified CAR-T cells express chemokine receptor(s) matching the tumor chemokine to facilitate migration to the 
tumor cells. B. Overcoming the immunosuppressive tumor microenvironment. 1) Anti-PD-L1-secreting CAR-T cells: human NK cells are recruited to the tumor site 
through secretion of anti-PD-L1 antibodies from CAR-T cells. 2) CAR-T cell therapy is potently enhanced by PD-1 blockade. 3) Blockade with the IL-10/TGFβ receptor. 4) 
Proinflammatory cytokines secreted by armored-CARs and TRUCKS (IL-12 showed an increased antitumor efficacy). C. Multiplex CAR-T cells to target the tumor 
profile. 1) Pooled CAR-T cells: multiple single-targeting CAR-T cells are mixed together. 2) Multi-specific CAR-T cells: one bispecific CAR-T cell consists of two specific CARs. 
3) Tandem CAR-T cells: two different CARs connected in tandem possessing a common intracellular domain. 4) Conditional CAR-T cells: one CAR has a CD3ζ signaling domain, 
and the other has a costimulatory domain. D. Minimizing CAR-T cell toxicity. 1) EGFRvIII CAR: EGFRvIII is the only truly tumor-specific antigen that is completely restricted 
to human cancer, such as glioblastoma. 2) Dual CAR: the first CAR activates T cell function through the CD3 signaling domain, and the second CAR contains CD28/CD137 to 
co-stimulate the signaling function. 3) Affinity-tuned CAR. 4) Inhibitory CAR (iCAR): normal cells are maintained safely because of negative signaling by iCARs that only have 
antigens that are expressed on normal cells. 5) ‘ON’ switch CAR-T cells: a CAR molecule is attached with a costimulatory CD3ζ signaling domain that can only be activated in 
the presence of a small molecule acting as an ‘ON’ switch. FAP: fibroblast activation protein; ECM: extracellular matrix; HPSE: heparanase; TRUCKs: T cells redirected for 
universal cytokine killing; CAR: chimeric antigen receptor. Note: The lines represent what A, B, C and D include respectively. 





co-express IL-12 (Figure 1B) [35, 69]. Equally, IL-12 
secretion by CAR-T cells has been shown to destroy 
antigen-negative cancer cells that may escape from 
the therapy [36]. Other studies have confirmed that 
the antitumor effects of CAR-T cells are enhanced by 
IL-2 and IL-15 production [70-74]. To rebalance the 
tumor microenvironment, armored CAR-T cells or 
redirected T cells for universal cytokine killing 
(TRUCKs) have been studied in preclinical trials. 
Koneru M et al. demonstrated that these armored 
CARs and TRUCKs secreted proinflammatory 
cytokines that induced transformation of the tumor 
microenvironment in mice with human ovarian 
cancer xenografts [75]. 
For treatment of cancers such as melanoma and 
renal cancer, the application of checkpoint inhibitors, 
such as anti-PD1, anti-CTLA-4 and anti-PD-L1, 
improves T cell responses in patients [41, 76]. 
Preclinical data showed that blocking PD1-mediated 
immunosuppression also boosts the therapeutic 
effects of CAR-T cells (Figure 1B) [41]. In a study of 
CAR-T cells with PD-1 blockade in a mouse model, 
Moon EK et al. found that PD-1 blockade improved 
the antitumor activity of human mesothelin-targeting 
CAR-T cells (Figure 1B) [77]. HER2-targeted CAR-T 
cells in combination with anti-PD-1 significantly 
eliminated tumor cells in a mouse model [41]. Suarez 
ER et al. engineered CAR-T cells to secrete anti-PD-L1 
antibodies instead of administering anti-PD-L1 
antibody [78]. This approach not only reduced tumor 
progression but also enabled human NK cells to 
migrate to the tumor sites in a mouse model of renal 
carcinoma. NK cells exert the anti-tumor efficiency 
through antibody-dependent cell-mediated 
cytotoxicity (ADCC) and IFNγ stimulation of CD8+ T 
cells [22]. Therefore, CAR-T cell therapy for solid 
tumors can be improved by infiltration of other 
immune cell subsets into the tumor 
microenvironment through local anti-PD-L1 antibody 
secretion. Interestingly, the number of MDSCs was 
also significantly diminished in the mouse tumor 
microenvironment. In addition, certain molecules, 
such as IL-6, may play double-sided roles in tumor 
microenvironment [79].  
6.3 Multiplexing CAR-T cells to target tumor profiles 
Given by tumor heterogeneity and antigen 
escape variants, the next development in CAR-T cell 
therapy is to target more than one antigens, similar to 
the combinatorial strategy of traditional 
chemotherapy [80]. This approach increases the 
chances of eliminating multiple sub-clonal 
populations simultaneously by targeting multiple 
TAAs or other factors in the tumor 
microenvironment.  
There are various ways to create multi-specific 
CAR-T cells. The basic approach is to construct a pool 
with two unispecific CAR-T cell products, namely, a 
‘CAR pool’, for simultaneous co-administration 
(Figure 1C) [81]. A strategy of using combination 
targeting of HER2 and IL13Rα2 by bispecific T cells in 
glioblastoma was shown to be more efficient in 
eliminating tumor cells and showed less antigen 
escape variants compared with the CAR-T cells 
targeting HER2 alone in both in vitro and in vivo 
mouse xenograft models [82]. When treating lung 
cancer, a similar approach was applied to pool 
EphA2-targeted CAR and FAPα-targeted CAR to 
target the tumor microenvironment. This combination 
showed significant tumor killing in vitro and 
prolonged the survival of mouse xenografts 
compared with application of either CAR alone [83]. 
A single T cell platform can also possess dual 
antigen targeting when two (bispecific [bi]CARs)[83] 
or more (triCARs) [84] unispecific CARs are expressed 
in T cells (Figure 1C) [81]. In breast cancer, the 
proliferation of biCAR-T cells targeting HER2 and 
MUC1 in vitro was dependent on contact with both 
antigens simultaneously. biCAR-T cells coexpressing 
HER2 and IL13Rα2 CAR molecules showed 
significant potential of eliminating tumor cells 
compared with unispecific CARs alone or pooled 
products in a glioblastoma model and the antigen 
escape variants also decreased substantially [83]. In a 
non-small cell lung cancer model, the combination of 
PSCA- and MUC1-targeting CAR-T cells 
synergistically eliminated PSCA and MUC1 positive 
tumor cells [84]. However, another study reported the 
biCAR-T cells did not enhance the level of IL-2, a 
marker of T cell activation compared with single 
CAR-T cells. This is possibly caused by the steric 
hindrance during simultaneously binding both 
antigens [85].  
CAR-T function can be improved by alteration of 
the CAR configuration. In a proof-of-concept study, a 
tandem (tan) CAR was designed by Grada et al. that 
had two different scFv domains in tandem linked by a 
spacer (Figure 1C) [81]. The tanCAR individually 
recognized each target antigen, and its function was 
strengthened when both antigens interacted with 
their scFv domain simultaneously in vitro and in vivo 
[85]. This phenomenon suggests co-docking occurring 
to both target molecules. This concept was also 
established in an inducible in vitro targeting model 
and in vitro and in vivo antigen escape models [86]. In 
addition to biCARs, triCARs, and tanCARs, 
neoantigen-like tissue factors (TFs) become promising 
novel antigens. In certain types of lung cancer, 
melanoma and other cancers, TFs are overexpressed 
on the surface of tumor cells, and TF-CAR-T cells 





were significantly activated to show specific 
cytotoxicity to TF-positive tumor cells in vitro [87]. 
Multispecific CAR-T cells have a potential 
advantage over unispecific CAR-T cells in avoiding 
on-target/off-tumor toxicities [49]. In lymphoreticular 
malignancies, instead of CRS, multispecific CAR-T 
cells led to specific tissue cholangitis [88]. A 
conditional biCAR was developed to minimize tissue 
damage (Figure 1C) [81]. Different endomembrane 
signaling domains are included in the two CARs of T 
cells, and T cell activation depends on simultaneous 
interaction of both CARs with their specific TAAs. For 
example, in prostate cancer, a biCAR was constructed 
with two prostate cancer antigens (prostate-specific 
membrane antigen and prostate stem cell antigen), the 
expression of which are also found on normal tissues. 
There is a CD3ζ intracellular domain and a 
CD28-4-1BB domain that constitute a costimulatory 
intracellular domain. This special biCAR effectively 
targeted tissues expressing both antigens but not 
tissues positive with single antigen [89]. Another 
example is that a conditional biCAR of mesothelin 
and α-folate receptor (FRα) with intracellular signaling 
domains of separated CD3ζ and CD28 are fully 
activated only when both antigens are present 
simultaneously in ovarian cancer. When 
multi-specific CAR-T cells were activated, cytokines 
were released and the tumor burden was reduced in 
both in vitro and in vivo experiments, similar to the 
single second generation of mesothelin-targeting 
CAR-T cells [90]. An approach of adding a further 
layer of titratable control to activate the CAR-T cells 
was recently described by Wu et al. The structure 
contained a small molecule that forms a 
heterodimerized biCAR, consisting of a binding 
domain for the antigen and a domain for intracellular 
signaling (Figure 1C) [81, 91]. 
Multitargeting CARs have several potential 
advantages over conventional unispecific CAR 
molecules. Through cytokine release and cytolysis in 
vitro and decreasing the tumor burden in vivo, the 
antitumor effects of CAR-T cells may be further 
enhanced. Other structures, such as the tanCAR, may 
strengthen functionality by changing steric 
interactions with tumor antigens [81]. However, the 
percentage of targeted tumor cells within tumor 
tissues should be concerned with multitargeting 
CARs [89, 92]. There are still growing demands to find 
novel antigens as potent targets. 
6.4 Minimizing CAR-T cell toxicity 
As mentioned above, to date, EGFRvIII is 
exclusively the tumor-specific CAR antigen, and it is 
fully restricted to human cancers and mostly found in 
glioblastoma [54, 55]. EGFRvIII-positive tumor cells 
can be precisely targeted by specific CAR-T cells to 
enhance therapeutic efficacy and decrease the 
corresponding toxicity. In an animal model study of 
glioblastoma, EGFRvIII CAR treatment produced 
very promising results, and clinical trials are 
underway to test it on glioblastoma patients [93, 94]. 
Various targeting strategies have been 
developed to increase the specificity and safety of 
CAR-T cell therapy (Figure 1D) [27]. One strategy is to 
modify T cells with two different CARs, and thus, 
tumor cells and normal cells can be induced to 
differentiate effectively. The first CAR molecule 
consists of the CD3ζ signaling domain, and the second 
CAR molecule contains the CD28 or CD137 
costimulation signaling domain [27, 89, 90]. Only 
when two CARs expressed in the same cells, the 
CAR-T cells can be fully activated. The 
on-target/off-tumor toxicities caused by TAA 
expression on normal tissues are limited by the CAR 
costimulatory domain on the same T cells. Preclinical 
data demonstrated that targeting multiple TAAs 
helps to minimize the possibility of antigen escape 
variant and efficiently target tumor subclones [81]. 
Furthermore, tumor specificity can be enhanced 
by an affinity-tuned CAR. In recent years, studies 
have demonstrated that adjusting the CAR affinity of 
CAR-T cells and maintaining potent antitumor 
efficacy in vivo, could distinguish tumor cells from 
normal cells with the expression of the same antigens 
at lower levels [51, 95]. Thus, tuning CAR sensitivity 
through high scFv affinity in CAR-T cell therapy for 
overexpressed antigens in solid tumors provides a 
promising approach. In addition, an alternative 
strategy called inhibitory CAR (iCAR) can reduce 
unwanted off-target effects. iCARs recognize specific 
antigens that are expressed only on normal cells, thus 
protects CAR-T cell from attacking normal cells by 
induction of the negative signaling. Fedorov et al. 
demonstrated that an iCAR possessing PD-1 and 
CTLA-4 inhibition ability prevented normal tissues 
from off-target effects in mouse models, applying the 
principle of checkpoint inhibition to an antigen in the 
normal tissue but not in the tumor [96]. However, due 
to the risk of iCAR to completely abolish T cell 
function, updated modifications, such as suicide 
genes, may be useful to control the unwanted toxicity 
[97]. 
The introduction of suicide switches, such as 
herpes simplex thymidine kinase (HSV-TK), inducible 
caspase 9 (iCasp9) and CD20, has already been 
clinically tested to control CAR-T cells [53, 98, 99]. 
This smart “tumor sensing” strategy, with the balance 
of two-antigen recognition, potentially diminishes 
on-target/off-tumor toxicity [100]. However, one 
disadvantage is the unintended elimination of the 





modified T cells. Transient RNA expression of CAR 
offers temporary redirected T cell activity and limits 
toxic side effects, even though, in solid tumor models, 
RNA CAR-T cell activity is limited by insufficient 
tumor infiltration [22]. 
Companion diagnostics for CAR-T cells 
Many reviews have exclusively discussed 
strategies to improve the efficacy of CAR-T cell 
therapy against solid tumors, while less attention has 
been paid to companion diagnostics and related 
detections. These diagnostics and detections are now 
becoming indispensable for CAR-T cell therapies as 
they are playing important roles in patient selection, 
disease outcome prediction, treatment regimen 
decisions, efficacy evaluation, and relapse prevention. 
In these regards, we would like to focus on the topics 
of detection of target antigen expression and the 
properties of CARs.  
Since the death report of a metastatic colon 
cancer patient caused by on-target/off-tumor effects 
of ERBB2-targeted CAR-T cell therapy in 2010, the 
side effects of CAR-T cell therapy for solid tumors 
have received extensive attention [22, 43]. The 
on-target/off-tumor effects of CAR-T cells are mainly 
caused by T cells attacking normal cells due to their 
expression of target antigens [50, 100]. Thus, there is 
the compelling need for the identification of TSAs for 
treating solid tumors with CAR-T cells. Unless the 
depletion of those normal cells is tolerable, similar to 
CD19+ B cells, CARs with moderate affinity are 
considered to improve the effect of CAR-T cell 
therapy [2, 27, 46, 101, 102]. Despite the lack of an 
ideal TSA, scientists have attempted to reduce the side 
effects of CAR-T cell therapies by investigating the 
extracellular domain of CARs, especially the affinity 
of the scFv domains. Studies have reported that 
reducing the affinity of CARs could spare normal cells 
that express the target antigen at a low level, thus 
avoiding the on-target/off-tumor effect [51, 95, 103]. 
With detail comparisons between the T cell receptors 
and CARs, more precise adjustments have been made 
to CARs [104, 105]. A CD38-targeted CAR with 
~1,000-fold reduced affinity was confirmed to be 
more suitable for treating multiple myeloma, and an 
ICAM-1-targeting CAR with micromolar affinity was 
more appropriate than nanomolar counterparts for 
treating solid tumors [102, 106]. In addition, the 
density of CARs on T cells is another factor that 
should be considered along with the affinity. 
Altogether, CARs with moderate affinity are suitable 
for targeting TAAs in solid tumors. However, there is 
still an important factor that impacts the affinity 
choice of CARs and should be considered: the density 
or expression level of the target antigens on tumor 
cells [107, 108].  
To test the expression level of the target antigens 
on tumor cells, immunohistochemical (IHC) staining 
is ubiquitously utilized for regimen decisions. 
Another point that should be highlighted is the 
differences between the antibodies used for IHC and 
those for CARs, within which the scFv domains are 
responsible for binding the target antigens. Thus, 
using an antibody with the same clone origin for IHC 
and scFv for CARs has been emphasized [108, 109]. 
Nevertheless, peptides may form different spatial 
structures under different circumstances, and this 
may hide some of the essential binding sites of the 
scFv domains compared with the related antibodies 
for IHC [110-113]. Thus, the optimal antibody for IHC 
tests should bind the same epitopes as the relative 
CAR, or be in form of custom-made scFv peptide by 
coupling with a tag for secondary antibody detection. 
When discussing the detection of target antigen 
expression on tumor tissues using IHC assays, a 
question should be raised about the patients who do 
not have tumor tissue samples available such as in the 
situation of early stage of disease or metastasis, and 
minimal residual disease (MRD). In order to test 
whether those patients are suitable for respective 
CAR-T treatement, an alternative approach may be 
found by detecting the expression of target antigens 
on circulating tumor cells (CTC). We have tested the 
applicability of this protocol by examining the 
expression of EGFR and mesothelin on CTCs for 
CAR-T cell therapy, because these antigens are 
frequently targeted in clinical trials (Figure 2) [114]. 
Our preliminary results as shown in Figure 2 
demonstrated the feasibility for adapting CTC as one 
of the companion diagnostic and monitoring tool for 
CAR-T therapy. However, there are key factors that 
should be considered with this approach before it can 
become a reliable clinical testing utility. First, the 
number of CTCs varies with cancer types and stages. 
In order to assure sufficient CTCs are obtained and 
analyzed, the optimal sample blood volume still 
remain to be determined because too few CTCs may 
lead to a false negative result. Second, the 
epithelial-mesenchymal phenotype of CTCs must be 
considered because the epithelial-mesenchymal 
transition (EMT) process may hide the expression of 
target antigens [115, 116]. Many currently available 
methods for CTCs enrichment do not take this into 
account, thus lead to another possibility for negative 
results. Finally, the correlation between the numbers 
of target antigen-positive CTCs and the therapeutic 
efficacy needs further investigation after treatment 
(Table 2). Beside IHC and CTC detection, many other 
methods and technologies, such as circulating tumor 
DNAs, circulating miRNAs, T-cell receptor 





sequencing/profiling and tumor mutation burdens, 
are currently being developed for companion 
diagnostics and efficacy monitoring for CAR-T cell 
therapy.  
 
Table 2. Summary of application of companion diagnostics 










scFv in CAR 
Apply the same clone 
origin of the antibody for 
IHC and scFv for CAR; 
Custom synthesis of the 
scFv peptide by coupling 
with the substrate for the 
second antibodies. 
Affinity tests Reduce the side 
effects of 
CAR-T cells for 
solid tumors 




Too low will 
cause inefficacy in 
killing cancer 
cells. 
Moderate affinity is 
proven to be a better 
choice; 
Balance the affinity and 
density of CAR on the T 
cells; 
Balance the affinity of 
CAR and density of the 
















e tumor cell 
relapse. 
CTCs are rare in 
blood; 






Confirm the correlation 
between the positivity of 
the antigen-repressing 
CTCs and tumor tissues; 
Extract more blood than 
the traditional volume; 
Investigate the 
correlation between the 
number of targeting 
antigen-positive CTCs 




In recent years, strategies have been applied to 
improve the efficacy and safety of CAR-T cell 
treatments for solid tumors, mainly through 
overcoming obstacles caused by the characteristics of 
T cells and tumor environment. Companion 
diagnostics, including IHC and CTC detection assays, 
can be applied to ameliorate the treatment of solid 
tumors with CAR-T cells. 
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